Effects of Microencapsulated Propolis and Turmeric in Patients With Chronic Kidney Disease

Launched by UNIVERSIDADE FEDERAL FLUMINENSE · Jan 4, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a combination of microencapsulated propolis and turmeric on inflammation in patients with chronic kidney disease (CKD) who are on hemodialysis. Chronic kidney disease can lead to inflammation and oxidative stress, which can harm patients and increase the risk of heart disease. Propolis and turmeric contain natural compounds that may help reduce inflammation and support the body’s ability to fight stress. The goal of the study is to see if taking these supplements can improve inflammatory markers in patients with advanced CKD.

To participate in the trial, patients must be between 65 and 74 years old, have stage 5 CKD (meaning their kidneys are functioning very poorly), and have been on hemodialysis for at least six months. Participants should also use a specific type of access for their treatment called an arteriovenous fistula. However, pregnant women, smokers, and those who have taken certain medications or supplements recently are not eligible. If you join the trial, you can expect to take the supplements and have your health monitored to see how they affect your inflammation levels.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with stage 5 CKD (GFR \< 15 mL/min);
• • On hemodialysis for more than 6 months;
• • Who have arteriovenous fistula (AVF) as vascular access
• Exclusion Criteria:
• • Pregnant women;
• • Smokers;
• • Using antibiotics in the last 3 months;
• • Using antioxidant supplements;
• • Who have habitual intake of propolis, curcumin and turmeric;
• • With autoimmune and infectious diseases, cancer, liver and AIDS (Acquired Immunodeficiency Syndrome)